Loading...
01/10 16:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Financial performance shows growth in sales and net income, but declining gross margins and increased expenses raise concerns. The Q&A reveals challenges in China and the U.S. market, with management hesitant to provide clear guidance. The lack of a shareholder return plan and macroeconomic uncertainties also weigh on sentiment. Despite some positives, such as market share gains, the overall outlook remains uncertain, leading to a neutral prediction for stock price movement.
Net Sales $88.6 million, up 10% from $80.3 million in Q3 2023. The increase is largely attributable to a $8 million or 10% increase in ICL sales.
Gross Profit $68.5 million or 77.3% of net sales, compared to $63.6 million or 79.2% in Q3 2023. The decrease in gross margin was primarily due to reduced unit production resulting in less absorption of fixed overhead.
Operating Expenses $62.8 million, up 10% from $57.3 million in Q3 2023. The increase reflects a shift in the timing of some spending that is expected to occur in Q4 2024.
G&A Expense $21.7 million, up from $19.3 million in Q3 2023, primarily due to increased facilities costs and compensation-related expenses.
Selling and Marketing Expense $26.6 million, unchanged from Q3 2023, but down from $28.8 million in Q2 2024 due to timing of marketing, promotion, and advertising activities.
R&D Expense $14.5 million, up from $11.5 million in Q3 2023, primarily due to purchases of in-process R&D related to external AI tools and compensation-related expenses.
GAAP Net Income $10 million or $0.20 earnings per diluted share, up from $4.8 million or $0.10 in Q3 2023. The increase was primarily due to higher sales and a gain on foreign currency transactions.
Adjusted EBITDA $16.2 million or $0.33 per diluted share, compared to $16.5 million or $0.33 in Q3 2023.
Cash and Cash Equivalents $236 million, up from $232.4 million in December 2023, providing significant flexibility for capital allocation.
Accounts Receivable Approximately $85 million, with expectations for DSO to moderate around 90 days.
CapEx Expected to be approximately $30 million for the full year 2024, including $10 million of ERP-related projects.
EVO ICL Experience Center: Celebrated the grand opening of the new EVO ICL Experience Center in Lake Forest, Southern California, designed to enhance training and education for surgeons and healthcare staff.
ICL Training Programs: Launched at least 10 training and education programs by year-end at the new center, including a comprehensive ICL boot camp for newly trained surgeons.
EVO ICL Technology: Surgeons increasingly view EVO ICL as the preferred choice for minus 6 diopters and above, reflecting positive feedback from educational investments.
Sales Growth in Americas: Generated 14% sales growth in the Americas, significantly outpacing the overall U.S. refractive market, which was down 18% year-over-year.
EMEA Sales Growth: Achieved 12% sales growth in EMEA, driven by strong performance in Middle East and European distributor markets.
APAC Sales Growth: Generated 9% sales growth in APAC, with China sales up 7%, despite a tapering of momentum in the latter part of Q3.
Gross Profit Margin: Gross profit margin for Q3 2024 was 77.3%, down from 79.2% year-over-year due to reduced unit production.
Operating Expenses: Total operating expenses increased 10% to $62.8 million, reflecting a shift in spending timing.
Market Positioning in China: Monitoring the dynamic macroeconomic landscape in China, with optimism following recent fiscal policy changes and stimulus announcements.
Highway 93 Initiative: Signed three additional Fast Lane agreements, now totaling 12, which commit customers to a significant portion of their refractive procedures.
Macroeconomic Environment: The macroeconomic environment softened in the second half of the quarter, particularly in China, impacting sales growth.
China Market Dynamics: Sales in China tapered off after Q2 earnings report, with a decline in consumer sentiment affecting sales momentum.
U.S. Refractive Market: The U.S. refractive market faced challenges, down 18% year-over-year, although STAAR outpaced the market with a 16% growth.
Regulatory and Competitive Pressures: Competition in the implantable lens category is increasing, with potential new entrants in the market, which may affect pricing and market share.
Supply Chain Challenges: There is a slight increase in inventory levels in China due to the slowdown in sales, which could impact future sales if not managed properly.
Economic Factors: The company is monitoring the impact of China's fiscal policy changes and stimulus on consumer sentiment and sales.
Operating Expenses: Operating expenses increased by 10%, reflecting higher facilities costs and compensation-related expenses, which could affect profitability.
Gross Margin: Gross profit margin is expected to decrease to approximately 79%, down 1 point from previous estimates due to reduced unit production.
EVO ICL Experience Center: Grand opening of a new center designed to enhance surgeon training and patient care, with plans to launch at least 10 educational programs by year-end.
Highway 93 Initiative: Continued expansion with three new Fast Lane agreements, resulting in significant sales growth among participating customers.
Surgeon Education and Training: Investment in education and training programs to build surgeon confidence in ICL technology, particularly for lower diopter strategies.
Market Share Growth: Outpacing the overall refractive market growth in the U.S. and other regions, with a focus on expanding total addressable market.
Fiscal Year 2024 Net Sales: Maintaining guidance of approximately $340 million to $345 million.
Gross Profit Margin: Expected to be approximately 79% for the full year, down 1 point from previous estimates.
CapEx for Fiscal Year 2024: Expected to be approximately $30 million, including $10 million for ERP-related projects.
Q4 2024 G&A Expense: Expected to be approximately $24 million.
Q4 2024 Selling and Marketing Expense: Expected to be approximately $32 million.
Q4 2024 R&D Expense: Expected to be approximately $15 million.
Long-term Growth Outlook: Confident in long-term growth potential, particularly in the context of evolving market dynamics and increasing myopia solutions.
Shareholder Return Plan: STAAR Surgical has not announced any specific share buyback or dividend program during this earnings call. The focus remains on maintaining a strong balance sheet with cash and investments totaling $236 million, which provides flexibility for future capital allocation decisions.
The earnings report shows significant declines in net sales and gross margin, especially in China, and an EBITDA loss. The Q&A reveals management's unclear responses regarding competition impact and withdrawn guidance, causing analyst concern. Despite some positive developments in ICL sales and market strategy, the lack of a share repurchase program and restructuring charges further weigh negatively. Given the market cap, the negative aspects are likely to outweigh the positives, leading to a negative stock price reaction.
The earnings call revealed significant challenges: a massive decline in sales, especially in China, and a drop in gross margin. Despite some optimism about future demand and cost optimization, the withdrawal of guidance due to economic uncertainty and competitive pressures add to investor concerns. The lack of a shareholder return plan and refusal to provide clear guidance further dampen sentiment. Given the small market cap, these factors are likely to result in a negative stock price movement over the next two weeks.
The earnings call reveals several concerns: a 3% net sales decline, significant losses in China, a net loss for fiscal 2024, and declining gross margins. The lack of a shareholder return plan and elevated inventory levels further dampen sentiment. Despite some optimism about future growth and the U.S. market, the Q&A session highlights uncertainties, particularly regarding competition and revenue recognition. The market cap suggests a moderate reaction, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.
The earnings call presents mixed signals. Financial performance shows growth in sales and net income, but declining gross margins and increased expenses raise concerns. The Q&A reveals challenges in China and the U.S. market, with management hesitant to provide clear guidance. The lack of a shareholder return plan and macroeconomic uncertainties also weigh on sentiment. Despite some positives, such as market share gains, the overall outlook remains uncertain, leading to a neutral prediction for stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
